Shadowing-Übung: Accurately Diagnosing the Soft Tissue Sarcoma - Englisch Sprechen Lernen mit YouTube
C2
You know, as our lead surgeon and one of the lead surgeons in the world,
148 Sätze
Wenn Sätze zu kurz oder zu lang sind, klicke auf Edit, um sie anzupassen.
1
You know, as our lead surgeon and one of the lead surgeons in the world,
2
I think it's always, you know,
3
very important that our surgical colleagues are dramatically involved in the treatment of sarcoma
4
because usually you're the gatekeeper in the entrance of a lot of this.
5
And so, you know, I think it would be good to ask you what your typical workup is for a patient
6
is suspected of having a sarcoma.
7
Sure, thanks, Brian.
8
You know, it's generally a patient will present to a primary care doctor
9
or an orthopedic surgeon or a general surgeon with a mass that is growing,
10
something that is changing, or maybe abdominal distension and discomfort.
11
But like we all learn in medical school,
12
a good history in physical is the first thing we do.
13
If this mass has been there for a long time,
14
it's less likely to be a malignant process or an aggressive malignant process.
15
If it's rapidly changing, the acuity is obviously there and something needs to be done about it.
16
But it's very important to stress the history and physical.
17
I always joke with my trainees that the most important test we order is the history and physical.
18
With that being said, we generally do recommend plain film imaging,
19
radiographs, orthogonal views in the extremity particularly,
20
because that can shed a lot of information in the area of cost containment.
21
If it's completely radiolucent in an extremity film,
22
it is very likely to be lipomatous,
23
well-differentiated liposarcoma at the worst,
24
versus if it has some calcifications on it,
25
the acuity is probably there and that it's a synovial sarcoma or potentially a higher grade liposarcoma,
26
things of that sort.
27
So radiographs are important and they're inexpensive.
28
Beyond that, we do think that advanced imaging is important before any biopsy is done.
29
We generally recommend an MRI in the extremity,
30
sometimes in the pelvis, but often a CT is adequate.
31
And if we really suspect that it's a sarcoma,
32
we prefer getting a chest CT first before any intervention is done.
33
But if you're seeing the patient in the clinic
34
and you're going to do a biopsy in the clinic because it's amenable to that,
35
you can hold off on some of that advanced imaging.
36
But we certainly recommend getting advanced imaging of the primary before any intervention is done.
37
As we all will talk about,
38
the most common site for these metastases is the chest,
39
and so we do think chest imaging is of paramount importance.
40
No, I agree, and I think it's always important to remember that,
41
you know, we hear lots of interesting things and you know,
42
car doors do not cause hematomas unless you're on blood thinners.
43
And so, you know, it's very important to always do that history and physical,
44
because these masses sometimes just get found by car doors.
45
Otherwise, you know, surgeons go and explore in the middle of a sarcoma,
46
and if you don't do these right,
47
I mean, you can get inferior outcomes.
48
And so, I mean, as we're moving through from the history and physical to imaging,
49
I think the next most important thing is really an understanding of diagnosis
50
and grading of these tumors and really what that means.
51
And I think maybe Dr. Jones can give us a little insight about how they approach that.
52
Thank you.
53
So as Dr. Patel mentioned,
54
these are heterogeneous and a complex group of diseases.
55
So it's very important to obtain a clear and accurate histological diagnosis prior to starting treatment.
56
Each histological subtype can have different clinical behavior due to different underlying biology and can also have a different treatment approach.
57
So it's important to have an experienced pathologist make the diagnosis prior to starting treatment.
58
The World Health Organization classification system is generally regarded as the standardized publication for classifying these tumors.
59
and it's very important that newer techniques such as molecular techniques are incorporated into the diagnosis as well.
60
In terms of grading, the most common grading system that's used is the French,
61
so-called French grading system, incorporating three grades,
62
high, intermediate and low, based on tumor differentiation, necrosis and mitotic count.
63
and the grading system has implications in terms of prognosis.
64
I think that's really, really important.
65
And, you know, in the year 2015 with our ability to sequence everybody
66
and our ability to look at all sorts of molecular markers,
67
you know, I think we're into a very complex world and a very rare group of tumors.
68
And so, you know, Jonathan,
69
what is your goals of molecular testing and how do you incorporate that into your practice?
70
Good question.
71
And thank you for the invitation to participate in the panel.
72
And I agree with, certainly with Shreyas and Robin,
73
regarding the complexity of sarcomas.
74
In fact, there's over 200 different types,
75
if you look at the pathology textbooks.
76
And I think that molecular testing is underutilized in the world of sarcoma and that it can help in diagnosis.
77
For instance, there are a number of histologies
78
that have specific genetic abnormalities such as gene amplification and MDM2 and some of the liposarcomas,
79
de-differentiated and well-differentiated.
80
And this testing can not only help make the diagnosis,
81
but there could also be therapeutic relevance.
82
For instance, in the era of targeted therapies,
83
we are now able to pair specific molecular events such as
84
a mutation in a gene called KIT in GI stromal tumor with a therapy such as imatinib
85
or sunitinib or regorafenib and be able to really precisely treat patients based on the molecular rearrangements or abnormalities.
86
And this is particularly pertinent to sarcoma since we have
87
so many histologic subtypes that have a very high frequency of these molecular abnormalities.
88
So, Brian, if I could add a few comments with this too.
89
I think has been well stated.
90
It's a huge number of different tumors.
91
And just like you would never classify carcinomas as one disease,
92
you wouldn't lump breast carcinoma and prostate carcinoma into the same thing.
93
We do that in sarcomas where we have these different diseases.
94
We lump together sarcomas because they're so rare and they can have similar presentations but markedly different genetics and different behavior.
95
And one of the key parts is to make sure,
96
as Robin was saying, that an expert in sarcoma pathologies reviewing the material,
97
especially
98
when it's obtained at a community hospital where pathologists may only
99
see a few cases of these in the course of their career.
100
The hierarchical testing that they do is based not just on the specimen they have,
101
but also based on the presentation of the patient.
102
So it's also very important that the medical
103
and surgical teams are in communication with the pathologist about the location of the tumor,
104
the behavior of the tumor, and those other aspects.
105
So a multidisciplinary approach is really important.
106
And their testing often looks at the shape of the cells first and where it is located,
107
and then that helps drive other testing like immunistic chemistry and other molecular testing.
108
I think we're still very early in the question of the wide-scale genomic testing that's performed either for research
109
or for clinical commercial purposes right now.
110
In our experience, and I think a lot of the other centers are doing this as well,
111
where we've sequenced large panels of genes,
112
we've seen a disappointingly few number of mutations that we didn't already expect in sarcomas.
113
I think it's still a very important area for research,
114
but personally I'm not yet ready to order huge screening panels for genetic mutations,
115
but instead stay focused, as John was just talking about based on the appearance of the tumor,
116
suspected appearance of the tumor,
117
and the possible mutation types.
118
Dr. Yeah, I'd like to,
119
if I may, an illustrative example is in the pediatric realm of a very practical fusion product,
120
you know, the fusion-associated tumors,
121
rhabdomyosarcoma, where historically it's been either in pediatric realm, conventionally alveolar versus embrinal.
122
And now it's actually fusion-driven,
123
and that's the gold standard.
124
And if there's some Pax-Foxo associated tumor that may have some embryonal features,
125
they're still going to call it alveolar.
126
And it's really that and the clinical trials moving forward through the Children's Inchology Group,
127
et cetera, are all doing this.
128
And I think Synovial and Ewings are following suit with that.
129
So it's really boots on the ground.
130
This is happening today, not just some academic ivory tower concept.
131
And I'd like to just highlight the importance of a multidisciplinary team in making the diagnosis.
132
Andy said, very often it's important to have the clinical features
133
and the radiological features together with the pathology to make the diagnosis.
134
And that's really, really important to highlight.
135
I think it's important to highlight the fact that the one thing that these are all mistaken for are melanomas,
136
and melanomas are, you know, they're mistaken for sarcomas.
137
And if you really make that error,
138
you've altered radically a treatment path for a patient.
139
And this is why having a highly experienced sarcoma pathologist confirming what they're seeing is really that important.
140
And what's very interesting is it's very hard,
141
I believe, to have the discussion we're having today
142
because we're talking about at least 80 different diseases that probably break up in six different categories of each one.
143
And we go from probably one of the best understood tumors on the planet,
144
which is the GI stromal tumor,
145
where we understand what mutations go with what drug,
146
to the undifferentiated pleomorphic sarcoma,
147
where we're still doing lots of clinical trials,
148
which we'll get into later.
App herunterladen
KI-Bewertung für jeden gesprochenen Satz
TRENDING
Beliebt
Warum mit diesem Video Sprechen üben?
Das Üben des Sprechens mit diesem Video bietet Lernenden eine hervorragende Gelegenheit, ihre Englische Aussprache zu verbessern und ein besseres Verständnis für medizinische Fachsprache zu entwickeln. Der Inhalt des Videos behandelt die Diagnose von Weichteilsarkomen, ein spezialisierter Bereich, der tiefergehende Sprachkenntnisse erfordert. Indem Sie die Argumente und Erklärungen des Sprechers nachvollziehen, können Sie nicht nur Ihre Sprachkenntnisse erweitern, sondern auch Ihr Selbstbewusstsein im Umgang mit medizinischen Themen stärken. Dies ist besonders wichtig für Studierende der Medizin oder für alle, die sich in einem gesundheitsbezogenen Beruf bewegen. Shadow speech und Englisch Shadowing sind effektive Methoden, um den Dialog nachzuahmen und den Sprachfluss zu trainieren.
Grammatik & Ausdrücke im Kontext
- Präsente für allgemeine Aussagen: Der Sprecher verwendet im Video oft das Präsens, um allgemeine Fakten zu präsentieren. Zum Beispiel: „Wenn diese Masse seit langem vorhanden ist...“ Diese Struktur zeigt, wie wichtig es ist, die richtige Zeitform im Kontext zu wählen.
- Modalverben zur Beratung: Die Verwendung von Modalverben wie „sollten“ oder „könnten“ ist entscheidend, wenn Ratschläge gegeben werden, zum Beispiel: „Wir empfehlen, eine MRT durchzuführen.“ Dies ist eine nützliche Struktur für das Geben und Empfangen von Empfehlungen.
- Konditionalsätze: Der Sprecher nutzt oft Konditionalsätze, um Bedingungen zu verdeutlichen, wie zum Beispiel „Wenn die Masse schnell wächst...“. Diese Struktur hilft beim Verständnis komplexer Zusammenhänge und Argumentationsführungen.
- Deskriptive Sprache: Der Einsatz von Adjektiven zur Beschreibung von Tumoren („hochgradig“, „gut differenziert“) erweitert den Wortschatz und das Verständnis medizinischer Terminologie.
Häufige Aussprachefallen
Im Video sind einige Wörter und Ausdrücke, die für Deutschsprachige schwieriger auszusprechen sind. Achten Sie besonders auf:
- Sarcoma: Dieses Wort kann aufgrund des „c“ und „r“ in der Mitte Schwierigkeiten bereiten. Es wird ‘sahr-koh-muh’ ausgesprochen.
- Imaging: Achten Sie auf die Betonung, sie wird oft 'im-uh-jing’ ausgesprochen. Die korrekte Betonung ist wichtig, um Fachgespräche zu führen.
- Histories: Ein weiterer herausfordernder Begriff, besonders die Pluralform 'histories’. Die richtige Aussprache ist 'his-tuh-reez' und muss klar ausgesprochen werden.
Indem Sie regelmäßig mit diesem Video üben und sich auf diese Aspekte konzentrieren, können Sie Ihre Englische Aussprache verbessern und Ihr Selbstvertrauen in Gesprächen stärken. Nutzen Sie shadow speak, um die zeitgemäßen medizinischen Ausdrücke und deren Aussprache zu meistern.
Was ist die Shadowing-Technik?
Shadowing ist eine wissenschaftlich fundierte Sprachlerntechnik, die ursprünglich für die professionelle Dolmetscherausbildung entwickelt und durch den Polyglotten Dr. Alexander Arguelles populär gemacht wurde. Die Methode ist einfach aber wirkungsvoll: Du hörst englisches Audio von Muttersprachlern und wiederholst es sofort laut — wie ein Schatten, der dem Sprecher mit nur 1–2 Sekunden Verzögerung folgt. Anders als passives Hören oder Grammatikübungen zwingt Shadowing dein Gehirn und deine Mundmuskulatur, gleichzeitig echte Sprachmuster zu verarbeiten und zu reproduzieren. Studien zeigen, dass es Aussprachegenauigkeit, Intonation, Rhythmus, verbundene Sprache, Hörverständnis und Sprechflüssigkeit signifikant verbessert — was es zu einer der effektivsten Methoden für die IELTS Speaking-Vorbereitung und reale englische Kommunikation macht.
☕ Kauf uns einen Kaffee
ShadowingEnglish bleibt 100% kostenlos dank deiner Unterstützung. Server- und KI-Kosten sind hoch — dein Kaffee hält uns am Laufen! 🙏